Karyopharm Therapeutics (KPTI) News Today

Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below Two Hundred Day Moving Average of $1.09

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendatio

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average of $1.12

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - HC Wainwright lifted their Q3 2024 earnings per share (EPS) estimates for Karyopharm Therapeutics in a research report issued on Wednesday, August 7th. HC Wainwright analyst E. White now expects that the company will post earnings per sha

StockNews.com raised shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.

HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday.

Robert W. Baird cut their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating on the stock in a research note on Wednesday.

Karyopharm Therapeutics (NASDAQ:KPTI) will be releasing earnings before the market opens on Tuesday, August 6, Zacks reports.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 18,890,000 shares, a decline of 12.7% from the June 30th total of 21,640,000 shares. Based on an average trading volume of 1,390,000 shares, the short-interest ratio is presently 13.6 days.

GSA Capital Partners LLP trimmed its stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 44.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,299,151 shares of the company's

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has received an average rating of "Moderate Buy" from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy

HC Wainwright decreased their price target on Karyopharm Therapeutics from $8.00 to $7.00 and set a "buy" rating for the company in a report on Friday.

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Above 50-Day Moving Average of $1.06

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) Director Deepika Pakianathan sold 231,548 shares of the stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $0.95, for a total value of $219,970.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a report issued on Sunday, June 2nd. Leerink Partnrs analyst J. Chang now expects that the company w

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) Director Deepika Pakianathan sold 204,394 shares of the business's stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $0.95, for a total value of $194,174.30. Following the sale, the director now owns 14,697 shares in the company, valued at $13,962.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of Karyopharm Therapeutics in a report on Thursday.